Mink Therapeutics (INKT) Stock
Early stage biotech developing cell based cancer treatments. Here's the price, business snapshot, and what's worth knowing about Mink Therapeutics in July 2026.
Mink Therapeutics, Inc. (INKT) is a small‑capitalisation biotechnology company (market cap about $67m) focused on developing cell‑based immunotherapies and related immune‑oncology approaches. Investors should know it is an early‑stage, research‑driven business: valuation tends to reflect scientific progress, clinical or preclinical milestones, partnerships and the ability to raise capital rather than steady revenues. That profile creates potential upside if programmes advance, but also significant downside from trial setbacks, regulatory hurdles, manufacturing complexity and financing risk. Shares can be highly volatile and subject to dilution from future fundraising. This summary is educational only and not personal investment advice; it is intended to help you understand the company’s business and risks. Suitable investors are typically those comfortable with long time horizons, high uncertainty and the possibility of loss. Always consider seeking independent financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MINK Therapeutics' stock with a target price of $8, suggesting growth potential.
Financial Health
Mink Therapeutics is producing solid cash flow per share, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring INKT
MASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: 18 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Cell therapy focus
Develops cell‑based immunotherapies and immune approaches; scientific progress can influence value, though clinical outcomes remain uncertain.
Early-stage potential
Small market cap can offer upside if milestones succeed, but shares are often volatile and future fundraising may dilute holders.
Regulatory pathway matters
Advancement depends on trial results and approvals across jurisdictions; commercialisation requires capital, manufacturing and partnerships.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.